What is BPC-157?

Your stomach secretes acid strong enough to strip paint. Day after day its lining sits in a bath near pH 1 — corrosive enough to break down meat, cartilage and bone — and yet it does not digest itself. The reason is chemistry: the gastric wall constantly produces protective compounds that defend and repair it faster than the acid can do harm. In the late 1990s, researchers in Zagreb went looking inside one of those protective proteins. What they isolated would become one of the most argued-about molecules in modern regenerative science.

They called it Body Protection Compound 157.

Where does BPC-157 actually come from?

BPC-157 is not something the body produces on its own in this form. It is a synthetic fragment — a sequence of 15 amino acids that researchers identified within a larger protective protein in human gastric juice, then reproduced in the laboratory.¹ The parent protein’s role is cytoprotection: shielding the cells that line one of the most hostile environments in the body. Remarkably, the small fragment kept some of that activity on its own.

The early story belongs almost entirely to one group: Predrag Sikirić and colleagues at the University of Zagreb, who from the 1990s published most of the foundational research and gave the molecule its second name, PL 14736.¹ For two decades BPC-157 lived inside their papers — a Croatian curiosity, studied in rats, all but unknown beyond a small circle of gut- and wound-healing scientists.

Why is a 15-amino-acid chain such a big deal?

Peptides are short chains of amino acids — the same building blocks as proteins, just fewer of them. The catch is that most peptides are fragile. Expose one to stomach acid and digestive enzymes and it tends to fall apart within minutes. That fragility is exactly why so many peptide drugs have to be injected rather than swallowed.

BPC-157 is unusual. In laboratory conditions it is notably stable — resistant to breakdown in gastric acid and stable in aqueous solution, where comparable peptides degrade.² For researchers that stability is the entire point: a molecule that survives long enough to be handled, characterised and tested is one you can actually run experiments on. It is also why formulation and quality control are a serious discipline here, not an afterthought — a thread we will pick up at the end.

What have researchers actually observed?

Nearly everything known about BPC-157 comes from animal and cell studies, and one theme recurs across them: angiogenesis, the growth of new blood vessels. Picture plumbing. Damaged tissue cannot rebuild without a fresh supply line of blood, oxygen and nutrients, and several lines of research suggest BPC-157 influences the signalling that lays down that new supply.

Mechanistically, preclinical work points to the nitric-oxide pathway and the VEGFR2 receptor — the cell’s main “grow vessels here” antenna — as central to the effects reported.⁶ Layered on that vascular signalling, separate rodent studies have described effects on tendon,³ ligament,⁴ and bone,⁵ and recent reviews have extended the conversation to broader tissue repair and pain pathways.⁷ The breadth is striking — gut, eye, nerve, vessel, musculoskeletal tissue. It is also, as we are about to see, part of the problem.

So how strong is the evidence, honestly?

Here, candour matters more than enthusiasm. In 2025 a team at the Hospital for Special Surgery in New York — among the world’s leading orthopaedic institutions — screened the BPC-157 literature for a systematic review.⁸

It helps to picture the ladder every compound has to climb, from test tube to approved medicine. Most peptide research never leaves the bottom rungs — and BPC-157 is no exception.

Where BPC-157 sits on the evidence ladder in 2026 — much of the conversation happens as if it were two rungs higher.

A separate narrative review the same year reached the same verdict in plain words: the compound “should be considered investigational.”⁹ A 2026 primer written for sports-medicine physicians went further still, noting that even basic clinical parameters — indications, dosing, duration — remain unknown.¹⁰ None of that makes the preclinical work uninteresting. It makes it preclinical — and the distance between “promising in rodents” and “proven in people” is wide, well-documented, and quietly skipped over in most of the places BPC-157 is now discussed.

Why is BPC-157 suddenly everywhere?

For twenty years this was a molecule only a gastroenterologist could love. Then it left the journals. In June 2026 the Huberman Lab podcast gave peptides a full episode, walking through BPC-157 alongside others — and, to its credit, repeatedly stressing how thin the human data is. Elsewhere the framing has been looser: BPC-157 shows up in athletes’ recovery routines, in the “Wolverine stack” name-dropped on the world’s biggest podcasts, in beauty columns, and in social-media videos with tens of millions of views.

Regulators have noticed. In the United States, BPC-157 sits on a short list of peptides under review by an FDA advisory committee in July 2026 — a process that could change how it is handled in compounding pharmacies. That is a US compounding question, however; in Europe the picture is different, and it is research-use-only status that governs how the compound is supplied here.

What does “research use only” actually mean?

It means exactly what it says. BPC-157 is not an approved medicine in the EU, and Condor supplies it for laboratory research only — not for human or veterinary use, and with no therapeutic claims. In a market where regulators have found that a large share of online peptide products are mislabelled or impure, that framing is not fine print to scroll past. It is the substance.

It is also why purity is not a slogan. A research compound is only as good as its characterisation: verified by HPLC, identity-confirmed by mass spectrometry, and documented batch by batch in a certificate of analysis. For a peptide whose entire scientific value rests on careful, repeatable experiments, knowing exactly what is in the vial is the line between data and noise.